Technology News and Research

RSS

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

Edge CT now available in NYU Langone's Department of Radiology clinical practice

NYU Langone Medical Center is the first in the country to offer patients access to the new Siemens Somatom Definition Edge single-source computed tomography system (Edge CT), one of the world's fastest CT scanners capable of generating high quality, 3-D diagnostic images using extremely low radiation.

28 Aug 2012

Process for setting new global development goals should be open, inclusive

In this CNN opinion piece, Jamie Drummond, co-founder and executive director of ONE, notes the 2015 deadline for the Millennium Development Goals (MDGs) is approaching, assesses progress towards these goals and examines issues surrounding the creation of a new set of goals.

28 Aug 2012

Researchers now add electronic sensors to tissue scaffolds

To control the three-dimensional shape of engineered tissue, researchers grow cells on tiny, sponge-like scaffolds. These devices can be implanted into patients or used in the lab to study tissue responses to potential drugs.

28 Aug 2012

Control of siRNA could aid regenerative medicine, cancer therapy

Some of the body's own genetic material, known as small interfering RNA (siRNA), can be packaged then unleashed as a precise and persistent technology to guide cell behavior, researchers at Case Western Reserve University report in the current issue of the journal, Acta Biomaterialia.

28 Aug 2012

Matrix Medical Network announces acquisition of Ascender

Matrix Medical Network, a national leader in prospective medical assessment services, announced today that it has acquired Ascender, a leading provider of integrated, advanced information technology to healthcare clients, in an all-cash transaction.

28 Aug 2012

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Depomed, Inc. today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology.

28 Aug 2012

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

28 Aug 2012

Virtua achieves significant clinical milestone in the adoption of electronic health records

Today, Siemens Healthcare has announced that Virtua, a multi-hospital healthcare system, has achieved a significant clinical milestone in the adoption of electronic health records.

27 Aug 2012

BioTime amends license agreement with University of Utah for HyStem technology

BioTime, Inc. announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products covered by the core patents underlying HyStem technology.

27 Aug 2012

Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Perrigo Company and Tris Pharma, Inc. today announced the commercial launch of a major new store brand product. The new product is equivalent to Delsym extended–release oral liquid suspension containing dextromethorphan polistirex and will be marketed under major U.S. retailer and wholesalers' store brands or own label brands.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Bode launches Rapid DNA Service to provide near real-time analysis

The Bode Technology Group, Inc. (Bode), a leading provider of innovative forensic DNA services, announced today the launch of their Rapid DNA Service to provide near real-time DNA analysis.

27 Aug 2012

BD announces acquisition of Sirigen

BD, a leading global medical technology company, announced today that it has acquired Sirigen Group Limited, a developer of unique polymer dyes that are used in flow cytometry and can be applied to other technologies.

From BD (Becton, Dickinson and Company) 27 Aug 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

New method helps engineer tissues with embedded nanoscale networks

A multi-institutional research team has developed a method for embedding networks of biocompatible nanoscale wires within engineered tissues. These networks—which mark the first time that electronics and tissue have been truly merged in 3D—allow direct tissue sensing and potentially stimulation, a potential boon for development of engineered tissues that incorporate capabilities for monitoring and stimulation, and of devices for screening new drugs.

27 Aug 2012

Baylor Plano first hospital to merge MEM software and Epoch platform for atrial fibrillation therapy

Baylor Plano became the first hospital in the world on Friday to merge two highly advanced technologies for atrial fibrillation therapy.

27 Aug 2012

New device can measure mass of individual molecules one at a time

A team led by scientists at the California Institute of Technology (Caltech) have made the first-ever mechanical device that can measure the mass of individual molecules one at a time.

27 Aug 2012

Results from Roche's trastuzumab emtansine Phase III trial on HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Roche has reported that updated results from its EMILIA Phase III trial show that patients treated with trastuzumab emtansine had a significant improvement in OS compared to those randomized to standard-of-care therapy.

27 Aug 2012